Clinical Trials
397 trialsTIM
Abnoba Gmbh
Study to Evaluate Exicorilant (CORT125281) in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer
Corcept Therapeutics
Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder
Boehringer Ingelheim
Ferumoxtran-10-enhanced MRI in Prostate Cancer Patients
Saving Patients' Lives Medical B.V.
Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers
Partner Therapeutics, Inc.
A Study of OMX-0407 in Patients With Previously Treated Solid Tumours That Can't be Removed Surgically
iOmx Therapeutics AG
ARTIA-Bladder
Varian, a Siemens Healthineers Company
JIVAN
Aurigene Discovery Technologies Limited
TEJAS-2
Aurigene Discovery Technologies Limited
ITIL-306 in Advanced Solid Tumors
Instil Bio
Dose Escalation and Dose Expansion Study of CPO-100 in Patients With Advanced Solid Tumors
Conjupro Biotherapeutics, Inc.
A Trial of SHR3680 in Prostate Cancer Patients Who Are Candidates for Radical Prostatectomy
Jiangsu HengRui Medicine Co., Ltd.
A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3720 Tablets
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
Sotio Biotech Inc.
EV-103
Astellas Pharma Inc
A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People With Cancer
Pfizer
CONTACT-03
Hoffmann-La Roche
CELLO-1
Ipsen
Trial of PRO1160 (GEN1160) in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) (PRO1160-001)
Genmab
DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies
Novartis
PRO1107 in Patients With Advanced Solid Tumors
Genmab
Safety and Activity Study of PSCA-Targeted CAR-T Cells (BPX-601) in Subjects With Selected Advanced Solid Tumors
Regeneron Pharmaceuticals
A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines.
Pfizer
The Present Study Aims to Compare Patients Who Receive the Investigational Product (177Lu-DOTA-rosopatamab) Plus Standard of Care, in Comparison to Standard of Care Only
Telix Pharmaceuticals (Innovations) Pty Limited
A Study to Investigate the Safety and Tolerability of Intravenous QEQ278 in Patients With Advanced Solid Tumors
Novartis
ABLE-41
Ferring Pharmaceuticals
Tamarack
MacroGenics
TEM-GU
Genenta Science
A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors
Takeda
A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers
Ocellaris Pharma, Inc.
Combo of Cabozantinib With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic CRPC
Exelixis
Futibatinib and Pembrolizumab Combination in the Treatment of Advanced or Metastatic Urothelial Carcinoma
Taiho Oncology, Inc.
A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle Invasive Bladder Cancer (NMIBC)
Astellas Pharma Inc
Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies
Bolt Biotherapeutics, Inc.
A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma
NiKang Therapeutics, Inc.
Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc)
NiKang Therapeutics, Inc.
Prime-boost Immunotherapeutic Trial in Men With Biochemical Recurrence After Definitive Local Therapy for Prostate Cancer
Barinthus Biotherapeutics
NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors
Nuvation Bio Inc.
Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205)
Incyte Corporation
Optimus
Incyte Corporation
PAVO
Tempus AI
A Study to Assess the Safety, Pharmacokinetics, and Efficacy of Intravenous (IV) ABBV-303, as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181), in Adults With Advanced Solid Tumors
AbbVie
A Study of HFB301001 in Adult Patients With Advanced Solid Tumors
HiFiBiO Therapeutics
Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
Incyte Corporation
Study of PULSAR-ICI +/- IMSA101 in Patients With Oligometastatic NSCLC and RCC
ImmuneSensor Therapeutics Inc.
Safety, Tolerability, Pharmacokinetics, and Efficacy of Acapatamab in Subjects With mCRPC
Amgen
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors
Incyte Corporation
A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors
Actym Therapeutics, Inc.
Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors
Day One Biopharmaceuticals, Inc.
Efficacy Study of a Urine DEK ELISA for Diagnosis of Bladder Cancer
Medical Diagnostic Laboratories, LLC